Recombinant Human EGF-L7(Discontinued)
Shipping Info:
For estimated delivery dates, please contact us at [email protected]
| Amount : | 10 µg |
| Purification : | Purity: >= 98% by SDS-PAGE gel and HPLC analyses. |
| Content : | This recombinant protein is supplied in lyophilized form. |
| AA sequence : | MYRPGRRVCA VRAHGDPVSE SFVQRVYQPF LTTCDGHRAC STYRTIYRTA YRRSPGLAPA RPRYACCPGW KRTSGLPGAC GAAICQPPCR NGGSCVQPGR CRCPAGWRGD TCQSDVDECS ARRGGCPQRC VNTAGSYWCQ CWEGHSLSAD GTLCVPKGGP PRVAPNPTGV DSAMKEEVQR LQSRVDLLEE KLQLVLAPLH SLASQALEHG LPDPGSLLVH SFQQLGRIDS LSEQISFLEE QLGSCSCKKD S |
| Alternative Name : | Epidermal growth factor-like protein 7, MEGF7, Multiple EGF-like domains protein 7, NOTCH4-like protein, VE-statin, Zneu1 |
Source:E.coliEGF-L7 (Epidermal growth factor-like protein 7, Multiple EGF-like domains protein 7, VE-statin) is a multi-domain protein containing two EGF-like domains and one EMI domain. It is expressed almost exclusively in endothelial cells and functions to promote normal development of the vascular system, particularly tubulogenesis. EGF-L7 is capable of antagonistic binding to Notch receptors, resulting in the inhibition of Notch signaling in HUVEC and neural stem cells. In research models inducing hypoxia and subsequent reoxygenation (H/R), EGF-L7 can inhibit ICAM-1 expression and enhance the inhibition of NF-kB activation. Additionally, EGF-L7 can chemoattract endothelial cells and bind to the extracellular matrix. The overexpression of EGF-L7 is observed in various cancers, and is generally correlated with increased metastasis and a poor prognosis. Recombinant Human EGF-L7 is a 27.4 kDa protein containing 251 amino acid residues.
|
There are currently no product reviews
|
.png "ACE2/HEK293 Stable Cell Line")
